Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CF PharmTechHKSE:02652 +0.81%15 Days Payable is 72.02 as of Dec. 2025, which is 2% below its 10-year median of 73.47. GuruFocus rates HKSE:02652 with a GF Score™ of 15/100. The stock has 5 warning signs investors should review. Among 925 Drug Manufacturers companies, CF PharmTech ranks worse than 59.68% on this metric.
The historical data trend for CF PharmTech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CF PharmTech Days Payable Chart
CF PharmTech Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Days Payable
58.62
74.91
75.99
72.02
CF PharmTech Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
Days Payable
58.62
74.91
75.99
72.02
HKSE:02652 vs ZTS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CF PharmTech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CF PharmTech Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CF PharmTech's Days Payable distribution charts can be found below:
* The bar in red indicates where CF PharmTech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
CF PharmTech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CF PharmTech (HKSE:02652) has a Days Payable of 72.02 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CF PharmTech and its competitors. This is near median its historical median of 73.47. Over the past decade, CF PharmTech's Days Payable has ranged from 58.62 to 75.99. According to the industry distribution chart, CF PharmTech ranks #552 out of 925 companies in the Drug Manufacturers industry, placing it in the top 59.7%.
Is CF PharmTech's Days Payable too high?
CF PharmTech's current Days Payable of 72.02 is near median its 10-year median of 73.47. Over the past 10 years, this metric has ranged from a low of 58.62 to a high of 75.99. The Drug Manufacturers industry median Days Payable is 89.79. CF PharmTech's value of 72.02 is 19.8% below this industry median. Based on the distribution chart, CF PharmTech ranks #552 out of 925 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, CF PharmTech has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does CF PharmTech's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CF PharmTech ranks #552 out of 925 companies for Days Payable. This places CF PharmTech in the lower half of its industry. The industry median Days Payable is 89.79. CF PharmTech's value of 72.02 is 19.8% below this benchmark. Historically, CF PharmTech's own Days Payable has ranged from 58.62 to 75.99 over the past decade. While the company's 10-year median is 73.47 vs. the industry median of 89.79, CF PharmTech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 89.79, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CF PharmTech's current Days Payable of 72.02 is 19.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CF PharmTech and its competitors. For the Drug Manufacturers industry, the median Days Payable is 89.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CF PharmTech's current Days Payable is 72.02, which is near median its own 10-year median of 73.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CF PharmTech stock overvalued right now?
CF PharmTech (HKSE:02652) has a current Days Payable of 72.02. The current Days Payable is 72.02, which is near median its 10-year median of 73.47 and 19.8% below the Drug Manufacturers industry median of 89.79. CF PharmTech's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For CF PharmTech (HKSE:02652), the current Days Payable is 72.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CF PharmTech Inc is engaged in inhalation drug delivery technology. It is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is a specialist in the development of complex inhalation formulations with high barriers to entry, and a platform-based pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, international regulatory filing, and commercialization. Leveraging its self-developed, globally integrated end-to-end capabilities, from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to small interfering RNA (siRNA) nucleic acid delivery platforms. Its therapeutic areas encompass respiratory diseases and nasal diseases.
15GF Score
Get the complete analysis for HKSE:02652
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02652 has been successfully added to your 
